USD 0.03
(-10.45%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 | 4.07 Million CAD | 16.01% |
2023 | 3.51 Million CAD | 32.99% |
2022 | 2.64 Million CAD | 1461.67% |
2021 | 169.28 Thousand CAD | 141.86% |
2020 | 69.99 Thousand CAD | 215.07% |
2019 | 22.21 Thousand CAD | -73.51% |
2018 | 83.87 Thousand CAD | -60.87% |
2017 | 214.35 Thousand CAD | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q3 | 4.18 Million CAD | 6.98% |
2024 Q4 | 4.07 Million CAD | -2.57% |
2024 FY | 4.07 Million CAD | 16.01% |
2024 Q2 | 3.91 Million CAD | 1.62% |
2024 Q1 | 3.85 Million CAD | 9.53% |
2023 Q1 | 2.35 Million CAD | -10.76% |
2023 Q3 | 2.78 Million CAD | 4.34% |
2023 Q2 | 2.67 Million CAD | 13.3% |
2023 FY | 3.51 Million CAD | 32.99% |
2023 Q4 | 3.51 Million CAD | 26.07% |
2022 Q2 | 1.27 Million CAD | 189.85% |
2022 Q4 | 2.64 Million CAD | 91.49% |
2022 FY | 2.64 Million CAD | 1461.67% |
2022 Q1 | 440.53 Thousand CAD | 160.24% |
2022 Q3 | 1.38 Million CAD | 8.12% |
2021 Q1 | 64.46 Thousand CAD | -7.9% |
2021 FY | 169.28 Thousand CAD | 141.86% |
2021 Q3 | 124.27 Thousand CAD | 47.87% |
2021 Q4 | 169.28 Thousand CAD | 36.22% |
2021 Q2 | 84.04 Thousand CAD | 30.37% |
2020 FY | 69.99 Thousand CAD | 215.07% |
2020 Q4 | 69.99 Thousand CAD | -81.73% |
2020 Q3 | 383.12 Thousand CAD | 3703.81% |
2020 Q2 | 10.07 Thousand CAD | -61.16% |
2020 Q1 | 25.93 Thousand CAD | 16.72% |
2019 FY | 22.21 Thousand CAD | -73.51% |
2019 Q2 | 22.67 Thousand CAD | -68.04% |
2019 Q4 | 22.21 Thousand CAD | 74.28% |
2019 Q1 | 70.92 Thousand CAD | -15.44% |
2019 Q3 | 12.74 Thousand CAD | -43.78% |
2018 Q3 | 34 Thousand CAD | -16.26% |
2018 Q2 | 40.6 Thousand CAD | 0.0% |
2018 Q4 | 83.87 Thousand CAD | 146.66% |
2018 FY | 83.87 Thousand CAD | -60.87% |
2018 Q1 | - CAD | -100.0% |
2017 FY | 214.35 Thousand CAD | 0.0% |
2017 Q4 | 214.35 Thousand CAD | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
American Bio Medica Corporation | 3.6 Million USD | -13.044% |
Arrayit Corporation | 7.49 Million USD | 45.594% |
Atlantic International Corp. | 3.82 Million USD | -6.53% |
Biocept, Inc. | 22.01 Million USD | 81.472% |
Bioqual, Inc. | 18.93 Million USD | 78.463% |
CardioGenics Holdings Inc | 1.79 Million USD | -127.231% |
DermTech, Inc. | 64.75 Million USD | 93.701% |
Global WholeHealth Partners Corporation | - USD | -Infinity% |
Hangzhou Tigermed Consulting Co., Ltd. | 734.97 Million USD | 99.445% |
HTG Molecular Diagnostics, Inc. | 12.38 Million USD | 67.071% |
iMD Companies, Inc. | 1.67 Million USD | -143.614% |
IDenta Corp. | 1.01 Million USD | -302.566% |
Interpace Biosciences, Inc. | 28.15 Million USD | 85.515% |
Integrative Health Technologies, Inc. | 297.94 Thousand USD | -1268.911% |
InVitro International | 78.99 Thousand USD | -5063.476% |
Lumos Diagnostics Holdings Limited | 19.72 Million USD | 79.327% |
Many Bright Ideas Technologies Inc. | 129.29 Thousand USD | -3054.466% |
Medical Imaging Corp. | 9.51 Million USD | 57.144% |
NovelStem International Corp. | 4.2 Million USD | 3.03% |
Optigenex Inc. | 9.57 Million USD | 57.384% |
PharmChem, Inc. | 558.64 Thousand USD | -630.091% |
Proteome Sciences plc | 18.48 Million USD | 77.94% |
Response Genetics, Inc | 15.86 Million USD | 74.295% |
Rennova Health, Inc. | 49.66 Million USD | 91.788% |
RushNet, Inc. | 6.23 Million USD | 34.627% |
ScreenPro Security Inc. | 1.6 Million USD | -154.821% |
Stella Diagnostics Inc. | 18 Million USD | 77.348% |
StageZero Life Sciences Ltd. | 8.2 Million USD | 50.285% |
Todos Medical Ltd. | 50.15 Million USD | 91.868% |